These findings suggest that GLP-1 RAs could play a crucial role in the management of HFpEF, particularly in patients with obesity, by targeting the underlying inflammatory processes and contributing to better overall cardiovascular outcomes. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.